Log In
BCIQ
Print this Print this
 

ONL-101, ONL101

  Manage Alerts
Collapse Summary General Information
Company ONL Therapeutics Inc.
DescriptionFas receptor (CD95) inhibitor
Molecular Target Fas receptor (CD95)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationRetinal detachment
Indication DetailsTreat acute retinal detachment
Regulatory Designation U.S. - Orphan Drug (Treat acute retinal detachment)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today